All In Biotech

Drug Trial Radar · NCT02518139

A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)

A Phase 3, 52-week, Randomized, Active-Controlled Parallel Group Study to Evaluate the Safety and Tolerability of Nebulized TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease

Last checked: Nov 19, 2026Latest source record: Feb 24, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,060 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,060

Actual

Start

Sep 2015

Primary completion

Jun 2017

Study completion Jun 2017

Sponsor

Lead sponsor
Mylan Inc.Industry
Sponsor type
Industry
Collaborators
Theravance Biopharma
First posted
Aug 7, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to measure the safety and tolerability of TD 4208, an investigational drug being developed to treat people with moderate to very severe COPD, compared to tiotropium.

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)

Interventions

  • TD-4208Drug

    Subjects receiving TD-4208 are blinded to one of two doses of 4208.

  • TiotropiumDrug

    There is not a placebo, there is an active comparator (Tiotropium) arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse Events: Frequency and SeverityTime frame: Baseline to Day 365

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Palmetto Medical Research Associates L.L.C

    Easley, South Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.